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Recommendations for the conduct, reporting, editing, and Publication of Scholarly
Work in Medical Journals*1. About the recommendations
1.1. Purpose of the recommendations
ICMJE developed these recommendations to review best prac-
tice and ethical standards in the conduct and reporting of research
and other material published in medical journals, and to help au-
thors, editors, and others involved in peer review and biomedical
publishing create and distribute accurate, clear, reproducible, un-
biased medical journal articles. The recommendations may also
provide useful insights into the medical editing and publishing
process for the media, patients and their families, and general
readers.
1.2. Who should use the recommendations?
These recommendations are intended primarily for use by au-
thors who might submit their work for publication to ICMJE mem-
ber journals. Many non-ICMJE journals voluntarily use these
recommendations (see www.icmje.org/journals.html). The ICMJE
encourages that use but has no authority to monitor or enforce it.
In all cases, authors should use these recommendations along
with individual journals' instructions to authors. Authors should
also consult guidelines for the reporting of speciﬁc study types
(e.g., the CONSORT guidelines for the reporting of randomized tri-
als); see http://equator-network.org.
Journals that follow these recommendations are encouraged to
incorporate them into their instructions to authors and to make
explicit in those instructions that they follow ICMJE recommenda-
tions. Journals that wish to be identiﬁed on the ICMJE website as
following these recommendations should notify the ICMJE secre-
tariat via e-mail at icmje@acponline.org. Journals that in the past
have requested such identiﬁcation but who no longer follow ICMJE
recommendations should use the same means to request removal
from this list.
The ICMJE encourages wide dissemination of these recommen-
dations and reproduction of this document in its entirety for
educational, not-for-proﬁt purposes without regard for copyright,
but all uses of the recommendations and document should direct
readers to www.icmje.org for the ofﬁcial, most recent version, as
the ICMJE updates the recommendations periodically when new
issues arise.
1.3. History of the recommendations
The ICMJE has produced multiple editions of this document,
previously known as the Uniform Requirements for Manuscripts
Submitted to Biomedical Journals (URMs). The URM was ﬁrst pub-
lished in 1978 as a way of standardizing manuscript format and
preparation across journals. Over the years, issues in publishing* Note: This is NOT an ofﬁcial version. Readers should go the most recent version
which may be found at www.icm-je.org.that went well beyond manuscript preparation arose, resulting in
development of a number of Separate Statements on editorial pol-
icy. The entire Uniform Requirements document was revised in
1997; sections were updated in May 1999 and May 2000. In
May 2001, the ICMJE revised the sections related to potential con-
ﬂicts of interest. In 2003, the committee revised and reorganized
the entire document and incorporated the Separate Statements
into the text, and revised it again in 2010. Previous versions of
this document can be found in the “Archives” section of www.
icmje.org. This version, now renamed “Recommendations for the
Conduct, Reporting, Editing, and Publication of Scholarly Work in
Medical Journals” (ICMJE Recommendations), was released in
2013.2. Roles and responsibilities of authors, contributors,
reviewers, editors, publishers, and owners
2.1. Deﬁning the role of authors and contributors
2.1.1. Why authorship matters
Authorship confers credit and has important academic, social,
and ﬁnancial implications. Authorship also implies responsibility
and accountability for published work. The following recommen-
dations are intended to ensure that contributors who have made
substantive intellectual contributions to a paper are given credit
as authors, but also that contributors credited as authors under-
stand their role in taking responsibility and being accountable for
what is published.
Because authorship does not communicate what contributions
qualiﬁed an individual to be an author, some journals now
request and publish information about the contributions of each
person named as having participated in a submitted study, at
least for original research. Editors are strongly encouraged to
develop and implement a contributorship policy. Such policies
remove much of the ambiguity surrounding contributions, but
leave unresolved the question of the quantity and quality of
contribution that qualify an individual for authorship. The ICMJE
has thus developed criteria for authorship that can be used by
all journals, including those that distinguish authors from other
contributors.2.1.2. Who is an author?
The ICMJE recommends that authorship be based on the
following 4 criteria:
1. Substantial contributions to the conception or design of the
work; or the acquisition, analysis, or interpretation of data for
the work; AND
2. Drafting the work or revising it critically for important intel-
lectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in
ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and
resolved.
In addition to being accountable for the parts of the work he or
she has done, an author should be able to identify which co-authors
are responsible for speciﬁc other parts of the work. In addition, au-
thors should have conﬁdence in the integrity of the contributions of
their co-authors.
All those designated as authors should meet all four criteria for
authorship, and all who meet the four criteria should be identiﬁed
as authors. Those who do not meet all four criteria should be
acknowledged-see Section 2.1.3 below. These authorship criteria are
intended to reserve the status of authorship for those who deserve
credit and can take responsibility for the work. The criteria are not
intended for use as a means to disqualify colleagues from authorship
who otherwisemeet authorship criteria by denying them the oppor-
tunity tomeet criterion#s 2 or 3. Therefore, all individuals whomeet
theﬁrst criterion shouldhave the opportunity to participate in the re-
view, drafting, and ﬁnal approval of the manuscript.
The individuals who conduct the work are responsible for iden-
tifying who meets these criteria and ideally should do so when
planning the work, making modiﬁcations as appropriate as the
work progresses. It is the collective responsibility of the authors,
not the journal to which the work is submitted, to determine that
all people named as authors meet all four criteria; it is not the
role of journal editors to determine who qualiﬁes or does not
qualify for authorship or to arbitrate authorship conﬂicts. If agree-
ment cannot be reached about who qualiﬁes for authorship, the in-
stitution(s) where the work was performed, not the journal editor,
should be asked to investigate. If authors request removal or addi-
tion of an author after manuscript submission or publication, jour-
nal editors should seek an explanation and signed statement of
agreement for the requested change from all listed authors and
from the author to be removed or added.
The corresponding author is the one individual who takes pri-
mary responsibility for communication with the journal during
the manuscript submission, peer review, and publication process,
and typically ensures that all the journal's administrative require-
ments, such as providing details of authorship, ethics committee
approval, clinical trial registration documentation, and gathering
conﬂict of interest forms and statements, are properly completed,
although these duties may be delegated to one or more coauthors.
The corresponding author should be available throughout the sub-
mission and peer review process to respond to editorial queries in a
timely way, and should be available after publication to respond to
critiques of the work and cooperate with any requests from the
journal for data or additional information should questions about
the paper arise after publication. Although the corresponding
author has primary responsibility for correspondence with the
journal, the ICMJE recommends that editors send copies of all cor-
respondence to all listed authors.
When a large multi-author group has conducted the work, the
group ideally should decide who will be an author before the
work is started and conﬁrm who is an author before submitting
the manuscript for publication. All members of the group named
as authors should meet all four criteria for authorship, including
approval of the ﬁnal manuscript, and they should be able to take
public responsibility for the work and should have full conﬁdence
in the accuracy and integrity of the work of other group authors.
They will also be expected as individuals to complete conﬂict-of-
interest disclosure forms.
Some large multi-author groups designate authorship by a
group name, with or without the names of individuals. When sub-
mitting a manuscript authored by a group, the corresponding
author should specify the group name if one exists, and clearlyidentify the group members who can take credit and responsibility
for the work as authors. The byline of the article identiﬁes who is
directly responsible for the manuscript, and MEDLINE lists as au-
thors whichever names appear on the byline. If the byline includes
a group name, MEDLINE will list the names of individual group
members who are authors or who are collaborators, sometimes
called non-author contributors, if there is a note associated with
the byline clearly stating that the individual names are elsewhere
in the paper and whether those names are authors or collaborators.
2.1.3. Non-author contributors
Contributors who meet fewer than all 4 of the above criteria for
authorship should not be listed as authors, but they should be
acknowledged. Examples of activities that alone (without other
contributions) do not qualify a contributor for authorship are acqui-
sition of funding; general supervision of a research group or general
administrative support; and writing assistance, technical editing,
language editing, and proofreading. Those whose contributions
do not justify authorship may be acknowledged individually or
together as a group under a single heading (e.g. “Clinical Investiga-
tors” or “Participating Investigators”), and their contributions
should be speciﬁed (e.g., “served as scientiﬁc advisors,” “critically
reviewed the study proposal,” “collected data,” “provided and cared
for study patients”, “participated in writing or technical editing of
the manuscript”).
Because acknowledgment may imply endorsement by acknowl-
edged individuals of a study's data and conclusions, editors are
advised to require that the corresponding author obtain written
permission to be acknowledged from all acknowledged individuals.
2.2. Author responsibilities-conﬂicts of interest
Public trust in the scientiﬁc process and the credibility of pub-
lished articles depend in part on how transparently conﬂicts of in-
terest are handled during the planning, implementation, writing,
peer review, editing, and publication of scientiﬁc work.
A conﬂict of interest exists when professional judgment con-
cerning a primary interest (such as patients' welfare or the validity
of research) may be inﬂuenced by a secondary interest (such as
ﬁnancial gain). Perceptions of conﬂict of interest are as important
as actual conﬂicts of interest.
Financial relationships (such as employment, consultancies,
stock ownership or options, honoraria, patents, and paid expert tes-
timony) are the most easily identiﬁable conﬂicts of interest and the
most likely to undermine the credibility of the journal, the authors,
and of science itself. However, conﬂicts can occur for other reasons,
such as personal relationships or rivalries, academic competition,
and intellectual beliefs. Authors should avoid entering in to agree-
ments with study sponsors, both for-proﬁt and nonproﬁt, that
interfere with authors' access to all of the study's data or that inter-
fere with their ability to analyze and interpret the data and to pre-
pare and publish manuscripts independently when andwhere they
choose.
2.2.1. Participants
All participants in the peer-review and publication process-not
only authors but also peer reviewers, editors, and editorial board
members of journals-must consider their conﬂicts of interest
when fulﬁlling their roles in the process of article review and pub-
lication and must disclose all relationships that could be viewed as
potential conﬂicts of interest.
2.2.1.1. Authors. When authors submit a manuscript of any type or
format they are responsible for disclosing all ﬁnancial and personal
relationships that might bias or be seen to bias their work. The
ICMJE has developed a Form for Disclosure of Conﬂicts of Interest to
facilitate and standardize authors' disclosures. ICMJE member jour-
nals require that authors use this form, and ICMJE encourages other
journals to adopt it.
2.2.1.2. Peer reviewers. Reviewers should be asked at the time they
are asked to critique a manuscript if they have conﬂicts of interest
that could complicate their review. Reviewers must disclose to ed-
itors any conﬂicts of interest that could bias their opinions of the
manuscript, and should recuse themselves from reviewing speciﬁc
manuscripts if the potential for bias exists. Reviewers must not use
knowledge of the work they're reviewing before its publication to
further their own interests.
2.2.1.3. Editors and journal staff. Editors who make ﬁnal decisions
about manuscripts should recuse themselves from editorial deci-
sions if they have conﬂicts of interest or relationships that pose po-
tential conﬂicts related to articles under consideration. Other
editorial staff members who participate in editorial decisions
must provide editors with a current description of their ﬁnancial
interests or other conﬂicts (as they might relate to editorial judg-
ments) and recuse themselves from any decisions in which a con-
ﬂict of interest exists. Editorial staff must not use information
gained through working with manuscripts for private gain. Editors
should publish regular disclosure statements about potential con-
ﬂicts of interests related to the commitments of journal staff. Guest
editors should follow these same procedures.
2.2.2. Reporting conﬂicts of interest
Articles should be publishedwith statements or supporting doc-
uments, such as the ICMJE conﬂict of interest form, declaring:
e Authors' conﬂicts of interest; and
e Sources of support for the work, including sponsor names along
with explanations of the role of those sources if any in study
design; collection, analysis, and interpretation of data; writing
of the report; the decision to submit the report for publication;
or a statement declaring that the supporting source had no such
involvement; and
e Whether the authors had access to the study data, with an
explanation of the nature and extent of access, including
whether access is on-going.
To support the above statements, editors may request that au-
thors of a study sponsored by a funder with a proprietary or ﬁnancial
interest in the outcome sign a statement, such as “I had full access to
all of the data in this study and I take complete responsibility for the
integrity of the data and the accuracy of the data analysis.”
2.3. Responsibilities in the submission and peer-review process
2.3.1. Authors
Authors should abide by all principles of authorship and decla-
ration of conﬂicts of interest detailed in Section 2.1 and 2.2 of this
document. A growing number of entities are advertising them-
selves as “medical journals” yet do not function as such (“predatory
journals”). Authors should be aware of the integrity, history, prac-
tices and reputation of the journals to which they submit manu-
scripts. Further guidance is available at http://www.wame.org/
about/principlesof-transparency-and-best-practice.
2.3.2. Journals
2.3.2.1. Conﬁdentiality. Manuscripts submitted to journals are priv-
ileged communications that are authors' private, conﬁdentialproperty, and authors may be harmed by premature disclosure of
any or all of a manuscript's details.
Editors therefore must not share information about manu-
scripts, including whether they have been received and are under
review, their content and status in the review process, criticism
by reviewers, and their ultimate fate, to anyone other than the au-
thors and reviewers. Requests from third parties to usemanuscripts
and reviews for legal proceedings should be politely refused, and
editors should do their best not to provide such conﬁdential mate-
rial should it be subpoenaed.
Editors must also make clear that reviewers should keep manu-
scripts, associated material, and the information they contain
strictly conﬁdential. Reviewers and editorial staff members must
not publicly discuss the authors' work, and reviewers must not
appropriate authors' ideas before the manuscript is published. Re-
viewers must not retain the manuscript for their personal use and
should destroy paper copies of manuscripts and delete electronic
copies after submitting their reviews.
When a manuscript is rejected, it is best practice for journals to
delete copies of it from their editorial systems unless retention is
required by local regulations. Journals that retain copies of rejected
manuscripts should disclose this practice in their Information for
Authors.
When a manuscript is published, journals should keep copies of
the original submission, reviews, revisions, and correspondence for
at least three years and possibly in perpetuity, depending on local
regulations, to help answer future questions about the work should
they arise.
Editors should not publish or publicize peer reviewers' com-
ments without permission of the reviewer and author. If journal
policy is to blind authors to reviewer identity and comments are
not signed, that identity must not be revealed to the author or
anyone else without the reviewers' expressed written permission.
Conﬁdentiality may have to be breached if dishonesty or fraud is
alleged, but editors should notify authors or reviewers if they
intend to do so and conﬁdentiality must otherwise be honored.
2.3.2.2. Timeliness. Editors should do all they can to ensure timely
processing of manuscripts with the resources available to them. If
editors intend to publish a manuscript, they should attempt to do
so in a timely manner and any planned delays should be negotiated
with the authors. If a journal has no intention of proceeding with a
manuscript, editors should endeavor to reject the manuscript as
soon as possible to allow authors to submit to a different journal.
2.3.2.3. Peer review. Peer review is the critical assessment of man-
uscripts submitted to journals by experts who are usually not part
of the editorial staff. Because unbiased, independent, critical assess-
ment is an intrinsic part of all scholarly work, including scientiﬁc
research, peer review is an important extension of the scientiﬁc
process.
The actual value of peer review is widely debated, but the pro-
cess facilitates a fair hearing for a manuscript among members of
the scientiﬁc community. More practically, it helps editors decide
whichmanuscripts are suitable for their journals. Peer review often
helps authors and editors improve the quality of reporting. It is the
responsibility of the journal to ensure that systems are in place for
selection of appropriate reviewers.
It is the responsibility of the editor to ensure that reviewers have
access to all materials that may be relevant to the evaluation of the
manuscript, including supplementary material for e-only publica-
tion, and to ensure that reviewer comments are properly assessed
and interpreted in the context of their declared conﬂicts of interest.
A peer-reviewed journal is under no obligation to send submit-
ted manuscripts for review, and under no obligation to follow
reviewer recommendations, favorable or negative. The editor of a
journal is ultimately responsible for the selection of all its content,
and editorial decisions may be informed by issues unrelated to the
quality of a manuscript, such as suitability for the journal. An editor
can reject any article at any time before publication, including after
acceptance if concerns arise about the integrity of the work.
Journalsmay differ in the number and kinds of manuscripts they
send for review, the number and types of reviewers they seek for
each manuscript, whether the review process is open or blinded,
and other aspects of the review process. For this reason and as a ser-
vice to authors, journals should publish a description of their peer-
review process. Journals should notify reviewers of the ultimate de-
cision to accept or reject a paper, and should acknowledge the
contribution of peer reviewers to their journal. Editors are encour-
aged to share reviewers' comments with coreviewers of the same
paper, so reviewers can learn from each other in the review process.
As part of peer review, editors are encouraged to review
research protocols, plans for statistical analysis if separate from
the protocol, and/or contracts associated with project-speciﬁc
studies. Editors should encourage authors to make such documents
publicly available at the time of or after publication, before accept-
ing such studies for publication. Some journals may require public
posting of these documents as a condition of acceptance for
publication.
Journal requirements for independent data analysis and for pub-
lic data availability are in ﬂux at the time of this revision, reﬂecting
evolving views of the importance of data availability for pre- and
post-publication peer review.
Some journal editors currently request a statistical analysis of
trial data by an independent biostatistician before accepting studies
for publication. Others ask authors to say whether the study data
are available to third parties to view and/or use/reanalyze, while
still others encourage or require authors to share their data with
others for review or reanalysis. Each journal should establish and
publish their speciﬁc requirements for data analysis and posting
in a place which potential authors can easily access. Some people
believe that true scientiﬁc peer review begins only on the date a pa-
per is published. In that spirit, medical journals should have a
mechanism for readers to submit comments, questions, or criti-
cisms about published articles, and authors have a responsibility
to respond appropriately and cooperate with any requests from
the journal for data or additional information should questions
about the paper arise after publication (see Section 3).
ICMJE believes investigators have a duty to maintain the pri-
mary data and analytic procedures underpinning the published re-
sults for at least 10 years. The ICMJE encourages the preservation of
these data in a data repository to ensure their longer-term
availability.2.3.2.4. Integrity. Editorial decisions should be based on the rele-
vance of a manuscript to the journal and on the manuscript's orig-
inality, quality, and contribution to evidence about important
questions. Those decisions should not be inﬂuenced by commercial
interests, personal relationships or agendas, or ﬁndings that are
negative or that credibly challenge accepted wisdom. In addition,
authors should submit for publication or otherwise make publicly
available, and editors should not exclude from consideration for
publication, studies with ﬁndings that are not statistically signiﬁ-
cant or that have inconclusive ﬁndings. Such studies may provide
evidence that combined with that from other studies through
meta-analysis might still help answer important questions, and a
public record of such negative or inconclusive ﬁndings may prevent
unwarranted replication of effort or otherwise be valuable for other
researchers considering similar work. Journals should clearly statetheir appeals process and should have a system for responding to
appeals and complaints.
2.3.3. Peer reviewers
Manuscripts submitted to journals are privileged communica-
tions that are authors' private, conﬁdential property, and authors
may be harmed by premature disclosure of any or all of a manu-
script's details. Reviewers therefore should keep manuscripts and
the information they contain strictly conﬁdential. Reviewers must
not publicly discuss authors' work and must not appropriate au-
thors' ideas before the manuscript is published. Reviewers must
not retain the manuscript for their personal use and should destroy
copies of manuscripts after submitting their reviews. Reviewers are
expected to respond promptly to requests to review and to submit
reviews within the time agreed. Reviewers' comments should be
constructive, honest, and polite. Reviewers should declare their
conﬂicts of interest and recuse themselves from the peer-review
process if a conﬂict exists.
2.4. Journal owners and editorial freedom
2.4.1. Journal owners
Owners and editors of medical journals share a common pur-
pose, but they have different responsibilities, and sometimes those
differences lead to conﬂicts.
It is the responsibility of medical journal owners to appoint and
dismiss editors. Owners should provide editors at the time of their
appointment with a contract that clearly states their rights and
duties, authority, the general terms of their appointment, and
mechanisms for resolving conﬂict. The editor's performance may
be assessed using mutually agreed-upon measures, including but
not necessarily limited to readership, manuscript submissions
and handling times, and various journal metrics.
Owners should only dismiss editors for substantial reasons, such
as scientiﬁc misconduct, disagreement with the long-term editorial
direction of the journal, inadequate performance by agreed-upon
performance metrics, or inappropriate behavior that is incompat-
ible with a position of trust.
Appointments and dismissals should be based on evaluations by
a panel of independent experts, rather than by a small number of
executives of the owning organization. This is especially necessary
in the case of dismissals because of the high value society places on
freedom of speech within science and because it is often the re-
sponsibility of editors to challenge the status quo in ways that
may conﬂict with the interests of the journal's owners.
A medical journal should explicitly state its governance and
relationship to a journal owner (eg, a sponsoring society).
2.4.2. Editorial freedom
The ICMJE adopts theWorld Association of Medical Editors' deﬁ-
nition of editorial freedom, which holds that editors-in-chief have
full authority over the entire editorial content of their journal and
the timing of publication of that content. Journal owners should
not interfere in the evaluation, selection, scheduling, or editing of
individual articles either directly or by creating an environment
that strongly inﬂuences decisions. Editors should base editorial de-
cisions on the validity of the work and its importance to the jour-
nal's readers, not on the commercial implications for the journal,
and editors should be free to express critical but responsible views
about all aspects of medicine without fear of retribution, even if
these views conﬂict with the commercial goals of the publisher.
Editors-in-chief should also have the ﬁnal say in decisions about
which advertisements or sponsored content, including supple-
ments, the journal will and will not carry, and they should have
ﬁnal say in use of the journal brand and in overall policy regarding
commercial use of journal content.
Journals are encouraged to establish an independent editorial
advisory board to help the editor establish and maintain editorial
policy. Editors should seek input as needed from a broad array of
advisers, such as reviewers, editorial staff, an editorial board, and
readers, to support editorial decisions and potentially controversial
expressions of opinion, and owners should ensure that appropriate
insurance is obtained in the event of legal action against the editors,
and should ensure that legal advice is available when necessary. If
legal problems arise, the editor should inform their legal adviser
and their owner and/or publisher as soon as possible. Editors
should defend the conﬁdentiality of authors and peer-reviewers
(names and reviewer comments) in accordance with ICMJE policy
(see Section 2.3.2.1). Editors should take all reasonable steps to
check the facts in journal commentary, including that in news sec-
tions and social media postings, and should ensure that staff work-
ing for the journal adhere to best journalistic practices including
contemporaneous note-taking and seeking a response from all
parties when possible before publication. Such practices in support
of truth and public interest may be particularly relevant in defense
against legal allegations of libel.
To secure editorial freedom in practice, the editor should have
direct access to the highest level of ownership, not to a delegated
manager or administrative ofﬁcer.
Editors and editors' organizations are obliged to support the
concept of editorial freedom and to draw major transgressions of
such freedom to the attention of the international medical, aca-
demic, and lay communities.2.5. Protection of research participants
When reporting research involving human data, authors should
indicate whether the procedures followed have been assessed by
the responsible review committee (institutional and national), or
if no formal ethics committee is available, were in accordance
with the Helsinki Declaration as revised in 2013 (www.wma.net/
en/30publications/10policies/b3/index.html). If doubt exists
whether the research was conducted in accordance with the Hel-
sinki Declaration, the authors must explain the rationale for their
approach and demonstrate that the institutional review body
explicitly approved the doubtful aspects of the study. Approval by
a responsible review committee does not preclude editors from
forming their own judgment whether the conduct of the research
was appropriate.
Patients have a right to privacy that should not be violated
without informed consent. Identifying information, including
names, initials, or hospital numbers, should not be published in
written descriptions, photographs, or pedigrees unless the infor-
mation is essential for scientiﬁc purposes and the patient (or parent
or guardian) gives written informed consent for publication.
Informed consent for this purpose requires that an identiﬁable pa-
tient be shown the manuscript to be published. Authors should
disclose to these patients whether any potential identiﬁable mate-
rial might be available via the Internet as well as in print after pub-
lication. Patient consent should be written and archived with the
journal, the authors, or both, as dictated by local regulations or
laws. Applicable laws vary from locale to locale, and journals should
establish their own policies with legal guidance. Since a journal that
archives the consent will be aware of patient identity, some jour-
nals may decide that patient conﬁdentiality is better guarded by
having the author archive the consent and instead providing the
journal with a written statement that attests that they have
received and archived written patient consent.Nonessential identifying details should be omitted. Informed
consent should be obtained if there is any doubt that anonymity
can be maintained. For example, masking the eye region in photo-
graphs of patients is inadequate protection of anonymity. If identi-
fying characteristics are de-identiﬁed, authors should provide
assurance, and editors should so note, that such changes do not
distort scientiﬁc meaning.
The requirement for informed consent should be included in the
journal's instructions for authors.When informed consent has been
obtained, it should be indicated in the published article. When
reporting experiments on animals, authors should indicate
whether institutional and national standards for the care and use
of laboratory animals were followed. Further guidance on animal
research ethics is available from the International Association of
Veterinary Editors' Consensus Author Guidelines on Animal Ethics
and Welfare (http://veteditors.org/ethicsconsensusguidelines.
html).
3. Publishing and editorial issues related to publication in
medical journals
3.1. Corrections and version control
Honest errors are a part of science and publishing and require
publication of a correction when they are detected. Corrections
are needed for errors of fact. Matters of debate are best handled
as letters to the editor, as print or electronic correspondence, or
as posts in a journal-sponsored online forum. Updates of previous
publications (e.g., an updated systematic review or clinical guide-
line) are considered a new publication rather than a version of a
previously published article.
If a correction is needed, journals should follow these minimum
standards:
 The journal should publish a correction notice as soon as
possible detailing changes from and citing the original publi-
cation; the correction should be on an electronic or numbered
print page that is included in an electronic or a print Table of
Contents to ensure proper indexing.
 The journal should also post a new article versionwith details of
the changes from the original version and the date(s) on which
the changes were made.
 The journal should archive all prior versions of the article. This
archive can be either directly accessible to readers or can be
made available to the reader on request.
 Previous electronic versions should prominently note that there
are more recent versions of the article.
 The citation should be to the most recent version. Errors serious
enough to invalidate a paper's results and conclusions may
require retraction.3.2. Scientiﬁc misconduct, expressions of concern, and retraction
Scientiﬁc misconduct includes but is not necessarily limited to
data fabrication; data falsiﬁcation including deceptive manipula-
tion of images; and plagiarism. Some people consider failure to
publish the results of clinical trials and other human studies a
form of scientiﬁc misconduct. While each of these practices is prob-
lematic, they are not equivalent. Each situation requires individual
assessment by relevant stakeholders.When scientiﬁcmisconduct is
alleged, or concerns are otherwise raised about the conduct or
integrity of work described in submitted or published papers, the
editor should initiate appropriate procedures detailed by such com-
mittees such as the Committee on Publication Ethics (COPE)
(publicationethics.org/resources/ﬂowcharts) and may choose to
publish an expression of concern pending the outcomes of those
procedures. If the procedures involve an investigation at the au-
thors' institution, the editor should seek to discover the outcome
of that investigation, notify readers of the outcome if appropriate,
and if the investigation proves scientiﬁc misconduct, publish a
retraction of the article. There may be circumstances in which no
misconduct is proven, but an exchange of letters to the editor could
be published to highlight matters of debate to readers.
Expressions of concern and retractions should not simply be a
letter to the editor. Rather, they should be prominently labelled,
appear on an electronic or numbered print page that is included
in an electronic or a print Table of Contents to ensure proper index-
ing, and include in their heading the title of the original article. On-
line, the retraction and original article should be linked in both
directions and the retracted article should be clearly labelled as
retracted in all its forms (Abstract, full text, PDF). Ideally, the au-
thors of the retraction should be the same as those of the article,
but if they are unwilling or unable the editor may under certain cir-
cumstances accept retractions by other responsible persons, or the
editor may be the sole author of the retraction or expression of
concern. The text of the retraction should explain why the article
is being retracted and include a complete citation reference to
that article. Retracted articles should remain in the public domain
and be clearly labelled as retracted.
The validity of previous work by the author of a fraudulent pa-
per cannot be assumed. Editors may ask the author's institution
to assure them of the validity of other work published in their jour-
nals, or theymay retract it. If this is not done, editors may choose to
publish an announcement expressing concern that the validity of
previously published work is uncertain.
The integrity of research may also be compromised by inappro-
priate methodology that could lead to retraction.
See COPE ﬂowcharts for further guidance on retractions and ex-
pressions of concern. See Section 4.1.3.7.1 for guidance about avoid-
ing referencing retracted articles.3.3. Copyright
Journals should make clear the type of copyright under which
work will be published, and if the journal retains copyright, should
detail the journal's position on the transfer of copyright for all types
of content, including audio, video, protocols, and data sets. Medical
journals may ask authors to transfer copyright to the journal. Some
journals require transfer of a publication license. Some journals do
not require transfer of copyright and rely on such vehicles as Crea-
tive Commons licenses. The copyright status of articles in a given
journal can vary: Some content cannot be copyrighted (for example,
articles written by employees of some governments in the course of
their work). Editors may waive copyright on other content, and
some content may be protected under other agreements.3.4. Overlapping publications
3.4.1. Duplicate submission
Authors should not submit the same manuscript, in the same or
different languages, simultaneously to more than one journal. The
rationale for this standard is the potential for disagreement when
two (or more) journals claim the right to publish a manuscript
that has been submitted simultaneously to more than one journal,
and the possibility that two or more journals will unknowingly and
unnecessarily undertake the work of peer review, edit the same
manuscript, and publish the same article.3.4.2. Duplicate and prior publication
Duplicate publication is publication of a paper that overlaps sub-
stantially with one already published, without clear, visible refer-
ence to the previous publication. Prior publication may include
release of information in the public domain.
Readers of medical journals deserve to be able to trust that what
they are reading is original unless there is a clear statement that the
author and editor are intentionally republishing an article (which
might be considered for historic or landmark papers, for example).
The bases of this position are international copyright laws, ethical
conduct, and cost-effective use of resources. Duplicate publication
of original research is particularly problematic because it can result
in inadvertent double-counting of data or inappropriate weighting
of the results of a single study, which distorts the available
evidence.
When authors submit a manuscript reporting work that has
already been reported in large part in a published article or is con-
tained in or closely related to another paper that has been submit-
ted or accepted for publication elsewhere, the letter of submission
should clearly say so and the authors should provide copies of the
related material to help the editor decide how to handle the sub-
mission. See also Section 4.2.
This recommendation does not prevent a journal from consid-
ering a complete report that follows publication of a preliminary
report, such as a letter to the editor or an abstract or poster dis-
played at a scientiﬁc meeting. It also does not prevent journals
from considering a paper that has been presented at a scientiﬁc
meeting but was not published in full, or that is being considered
for publication in proceedings or similar format. Press reports of
scheduled meetings are not usually regarded as breaches of this
rule, but they may be if additional data tables or ﬁgures enrich
such reports. Authors should also consider how dissemination of
their ﬁndings outside of scientiﬁc presentations at meetings may
diminish the priority journal editors assign to their work.
In the event of a public health emergency (as deﬁned by public
health ofﬁcials), information with immediate implications for pub-
lic health should be disseminated without concern that this will
preclude subsequent consideration for publication in a journal.
Sharing with public media, government agencies, or manufac-
turers the scientiﬁc information described in a paper or a letter to
the editor that has been accepted but not yet published violates
the policies of many journals. Such reporting may be warranted
when the paper or letter describes major therapeutic advances;
reportable diseases; or public health hazards, such as serious
adverse effects of drugs, vaccines, other biological products, medi-
cal devices. This reporting, whether in print or online, should not
jeopardize publication, but should be discussed with and agreed
upon by the editor in advance when possible.
The ICMJE will not consider as prior publication the posting of
trial results in any registry that meets the criteria noted in Section
3.12 if results are limited to a brief (500word) structured abstract or
tables (to include patients enrolled, key outcomes, and adverse
events). The ICMJE encourages authors to include a statement
with the registration that indicates that the results have not yet
been published in a peer-reviewed journal, and to update the re-
sults registry with the full journal citation when the results are
published.
Editors of different journals may together decide to simulta-
neously or jointly publish an article if they believe that doing so
would be in the best interest of public health. However, the Na-
tional Library of Medicine (NLM) indexes all such simultaneously
published joint publications separately, so editors should include
a statement making the simultaneous publication clear to readers.
Authors who attempt duplicate publication without such notiﬁ-
cation should expect at least prompt rejection of the submitted
manuscript. If the editor was not aware of the violations and the
article has already been published, then the article might warrant
retraction with or without the author's explanation or approval.
See COPE ﬂowcharts for further guidance on handling duplicate
publication.
3.4.3. Acceptable secondary publication
Secondary publication of material published in other journals or
online may be justiﬁable and beneﬁcial, especially when intended
to disseminate important information to the widest possible audi-
ence (e.g., guidelines produced by government agencies and profes-
sional organizations in the same or a different language). Secondary
publication for various other reasons may also be justiﬁable pro-
vided the following conditions are met:
1. The authors have received approval from the editors of both
journals (the editor concerned with secondary publication must
have access to the primary version).
2. The priority of the primary publication is respected by a publi-
cation interval negotiated by both editors with the authors.
3. The paper for secondary publication is intended for a different
group of readers; an abbreviated version could be sufﬁcient.
4. The secondary version faithfully reﬂects the data and in-
terpretations of the primary version.
5. The secondary version informs readers, peers, and documenting
agencies that the paper has been published in whole or in part
elsewhere-for example, with a note that might read, “This
article is based on a study ﬁrst reported in the [journal title, with
full reference]”-and the secondary version cites the primary
reference.
6. The title of the secondary publication should indicate that it is a
secondary publication (complete or abridged republication or
translation) of a primary publication. Of note, the NLM does not
consider translations to be “republications” and does not cite or
index themwhen the original article was published in a journal
that is indexed in MEDLINE.
When the same journal simultaneously publishes an article in
multiple languages, the MEDLINE citation will note the multiple
languages (for example, Angelo M. Journal networking in nursing:
a challenge to be shared. Rev Esc Enferm USP. 2011 Dec 45
[6]:1281-2,1279- 80,1283-4. Article in English, Portuguese, and
Spanish. No abstract available. PMID 22241182).
3.4.4. Manuscripts based on the same database
If editors receive manuscripts from separate research groups or
from the same group analyzing the same data set (for example,
from a public database, or systematic reviews or meta-analyses of
the same evidence), the manuscripts should be considered inde-
pendently because they may differ in their analytic methods, con-
clusions, or both. If the data interpretation and conclusions are
similar, it may be reasonable although not mandatory for editors
to give preference to the manuscript submitted ﬁrst. Editors might
consider publishing more than one manuscript that overlap in this
way because different analytical approaches may be complemen-
tary and equally valid, but manuscripts based upon the same data-
set should add substantially to each other to warrant consideration
for publication as separate papers, with appropriate citation of pre-
vious publications from the same dataset to allow for transparency.
Secondary analyses of clinical trial data should cite any primary
publication, clearly state that it contains secondary analyses/re-
sults, and use the same identifying trial registration number as
the primary trial.
Sometimes for large trials it is planned from the beginning to
produce numerous separate publications regarding separateresearch questions but using the same original patient sample. In
this case authors may use the original single trial registration num-
ber, if all the outcome parameters were deﬁned in the original
registration. If the authors registered several substudies as separate
entries in, for example, clinicaltrials.gov, then the unique trial iden-
tiﬁer should be given for the study in question, The main issue is
transparency, so no matter what model is used it should be obvious
for the reader.
3.5. Correspondence
Medical journals should provide readers with a mechanism for
submitting comments, questions, or criticisms about published ar-
ticles, usually but not necessarily always through a correspondence
section or online forum. The authors of articles discussed in corre-
spondence or an online forum have a responsibility to respond to
substantial criticisms of their work using those same mechanisms
and should be asked by editors to respond. Authors of correspon-
dence should be asked to declare any competing or conﬂicting
interests.
Correspondence may be edited for length, grammatical correct-
ness, and journal style. Alternatively, editors may choose to make
available to readers unedited correspondence, for example, via an
online commenting system. Such commenting is not indexed in
Medline unless it is subsequently published on a numbered elec-
tronic or print page. However the journal handles correspondence,
it should make known its practice. In all instances, editors must
make an effort to screen discourteous, inaccurate, or libellous
comments.
Responsible debate, critique and disagreement are important
features of science, and journal editors should encourage such
discourse ideally within their own journals about the material
they have published. Editors, however, have the prerogative to
reject correspondence that is irrelevant, uninteresting, or lacking
cogency, but they also have a responsibility to allow a range of opin-
ions to be expressed and to promote debate.
In the interests of fairness and to keep correspondence within
manageable proportions, journals may want to set time limits for
responding to published material and for debate on a given topic.
3.6. Fees
Journals should be transparent about their types of revenue
streams. Any fees or charges that are required for manuscript pro-
cessing and/or publishing materials in the journal shall be clearly
stated in a place that is easy for potential authors to ﬁnd prior to
submitting their manuscripts for review or explained to authors
before they begin preparing their manuscript for submission
(http://publicationethics.org/ﬁles/u7140/Principles_of_
Transparency_and_Best_Practice_in_Scholarly_Publishing.pdf).
3.7. Supplements, theme issues, and special series
Supplements are collections of papers that deal with related is-
sues or topics, are published as a separate issue of the journal or as
part of a regular issue, andmay be funded by sources other than the
journal's publisher. Because funding sources can bias the content of
supplements through the choice of topics and viewpoints, journals
should adopt the following principles, which also apply to theme
issues or special series that have external funding and/or guest
editors:
1. The journal editor must be given and must take full re-
sponsibility for the policies, practices, and content of supple-
ments, including complete control of the decision to select
authors, peer reviewers, and content for the supplement. Edit-
ing by the funding organization should not be permitted.
2. The journal editor has the right to appoint one or more external
editors of the supplement and must take responsibility for the
work of those editors.
3. The journal editor must retain the authority to send supplement
manuscripts for external peer review and to reject manuscripts
submitted for the supplement with or without external review.
These conditions should be made known to authors and any
external editors of the supplement before beginning editorial
work on it.
4. The source of the idea for the supplement, sources of funding for
the supplement's research and publication, and products of the
funding source related to content considered in the supplement
should be clearly stated in the introductory material.
5. Advertising in supplements should follow the same policies as
those of the primary journal.
6. Journal editors must enable readers to distinguish readily be-
tween ordinary editorial pages and supplement pages.
7. Journal and supplement editors must not accept personal favors
or direct remuneration from sponsors of supplements.
8. Secondary publication in supplements (republication of papers
published elsewhere) should be clearly identiﬁed by the citation
of the original paper and by the title.
9. The same principles of authorship and disclosure of potential
conﬂicts of interest discussed elsewhere in this document
should be applied to supplements.3.8. Sponsorship or partnership
Various entitiesmay seek interactions with journals or editors in
the form of sponsorships, partnerships, meetings, or other types of
activities. To preserve editorial independence, these interactions
should be governed by the same principles outlined above for Sup-
plements, Theme Issues and Special Series (Section 3.7).
3.9. Electronic publishing
Most medical journals are now published in electronic as well as
print versions, and some are published only in electronic form.
Principles of print and electronic publishing are identical, and the
recommendations of this document apply equally to both. Howev-
er, electronic publishing provides opportunities for versioning and
raises issues about link stability and content preservation that are
addressed here.
Recommendations for corrections and versioning are detailed in
Section 3.1.
Electronic publishing allows linking to sites and resources
beyond journals over which journal editors have no editorial con-
trol. For this reason, and because links to external sites could be
perceived as implying endorsement of those sites, journals should
be cautious about external linking. When a journal does link to
an external site, it should state that it does not endorse or take re-
sponsibility or liability for any content, advertising, products, or
other materials on the linked sites, and does not take responsibility
for the sites' availability.
Permanent preservation of journal articles on a journal's web-
site, or in an independent archive or a credible repository is essen-
tial for the historical record. Removing an article from a journal's
website in its entirety is almost never justiﬁed as copies of the
article may have been downloaded even if its online posting was
brief. Such archives should be freely accessible or accessible to
archive members. Deposition in multiple archives is encouraged.
However, if necessary for legal reasons (e.g., libel action), the URLfor the removed article must contain a detailed reason for the
removal, and the article must be retained in the journal's internal
archive.
Permanent preservation of a journal's total content is the re-
sponsibility of the journal publisher, who in the event of journal
termination should be certain the journal ﬁles are transferred to a
responsible third party who can make the content available.
Journal websites should post the date that nonarticle web pages,
such as those listing journal staff, editorial board members, and in-
structions for authors, were last updated.
3.10. Advertising
Most medical journals carry advertising, which generates in-
come for their publishers, but journals should not be dominated
by advertisements, and advertising must not be allowed to inﬂu-
ence editorial decisions.
Journals should have formal, explicit, written policies for adver-
tising in both print and electronic versions. Best practice prohibits
selling advertisements intended to be juxtaposed with editorial
content on the same product. Advertisements should be clearly
identiﬁable as advertisements. Editors should have full and ﬁnal
authority for approving print and online advertisements and for
enforcing advertising policy.
Journals should not carry advertisements for products proven to
be seriously harmful to health. Editors should ensure that existing
regulatory or industry standards for advertisements speciﬁc to
their country are enforced, or develop their own standards. The in-
terests of organizations or agencies should not control classiﬁed
and other nondisplay advertising, except where required by law.
Editors should consider all criticisms of advertisements for
publication.
3.11. Journals and the media
Journals' interactions withmedia should balance competing pri-
orities. The general public has a legitimate interest in all journal
content and is entitled to important information within a reason-
able amount of time, and editors have a responsibility to facilitate
that. However media reports of scientiﬁc research before it has
been peer-reviewed and fully vetted may lead to dissemination of
inaccurate or premature conclusions, and doctors in practice need
to have research reports available in full detail before they can
advise patients about the reports' conclusions.
An embargo system has been established in some countries and
by some journals to assist this balance, and to prevent publication
of stories in the general media before publication of the original
research in the journal. For the media, the embargo creates a “level
playing ﬁeld,” which most reporters and writers appreciate since it
minimizes the pressure on them to publish stories before compet-
itors when they have not had time to prepare carefully. Consistency
in the timing of public release of biomedical information is also
important in minimizing economic chaos, since some articles
contain information that has potential to inﬂuence ﬁnancial mar-
kets. The ICMJE acknowledges criticisms of embargo systems as be-
ing selfserving of journals' interests and an impediment to rapid
dissemination of scientiﬁc information, but believe the beneﬁts of
the systems outweigh their harms.
The following principles apply equally to print and electronic
publishing and may be useful to editors as they seek to establish
policies on interactions with the media:
Editors can foster the orderly transmission of medical infor-
mation from researchers, through peer-reviewed journals, to
the public. This can be accomplished by an agreement with
authors that they will not publicize their work while their
manuscript is under consideration or awaiting publication and
an agreement with the media that they will not release stories
before publication of the original research in the journal, in
return for which the journal will cooperate with them in pre-
paring accurate stories by issuing, for example, a press release.
 Editors need to keep in mind that an embargo systemworks on
the honor system-no formal enforcement or policing mecha-
nism exists. The decision of a signiﬁcant number of media out-
lets or biomedical journals not to respect the embargo system
would lead to its rapid dissolution.
 Notwithstanding authors' belief in their work, very little medi-
cal research has such clear and urgently important clinical im-
plications for the public's health that the news must be released
before full publication in a journal. When such exceptional cir-
cumstances occur, the appropriate authorities responsible for
public health should decidewhether to disseminate information
to physicians and the media in advance and should be respon-
sible for this decision. If the author and the appropriate au-
thorities wish to have a manuscript considered by a particular
journal, the editor should be consulted before any public release.
If editors acknowledge the need for immediate release, they
should waive their policies limiting prepublication publicity.
 Policies designed to limit prepublication publicity should not
apply to accounts in the media of presentations at scientiﬁc
meetings or to the abstracts from these meetings (see Duplicate
Publication). Researchers who present their work at a scientiﬁc
meeting should feel free to discuss their presentations with
reporters but should be discouraged from offering more detail
about their study than was presented in the talk, or should
consider how giving such detail might diminish the priority
journal editors assign to their work (see Duplicate Publication).
 When an article is close to being published, editors or journal
staff should help the media prepare accurate reports by
providing news releases, answering questions, supplying
advance copies of the article, or referring reporters to appro-
priate experts. This assistance should be contingent on the
media's cooperation in timing the release of a story to coincide
with publication of the article.3.12. Clinical trial registration
The ICMJE's clinical trial registration policy is detailed in a series
of editorials (see Updates and Editorials [www.icmje.org/update.
html] and FAQs [www.icmje.org/faq_clinical.html]).
Brieﬂy, the ICMJE requires, and recommends that all medical
journal editors require, registration of clinical trials in a public trials
registry at or before the time of ﬁrst patient enrollment as a condi-
tion of consideration for publication. Editors requesting inclusion of
their journal on the ICMJE website list of publications that follow
ICMJE guidance [icmje.org/journals.html] should recognize that
the listing implies enforcement by the journal of ICMJE's trial regis-
tration policy.
The ICMJE deﬁnes a clinical trial as any research project that pro-
spectively assigns people or a group of people to an intervention,
with or without concurrent comparison or control groups, to study
the cause-and-effect relationship between a health-related inter-
vention and a health outcome. Health-related interventions are
those used tomodify a biomedical or health-related outcome; exam-
ples include drugs, surgical procedures, devices, behavioral treat-
ments, educational programs, dietary interventions, quality
improvement interventions, and process-of-care changes. Health
outcomes are any biomedical or health-related measures obtained
in patients or participants, including pharmacokinetic measuresand adverse events. The ICMJE does not deﬁne the timing of ﬁrst pa-
tient enrollment, but best practicedictates registration by the timeof
ﬁrst patient consent.
The ICMJE accepts registration in any registry that is a primary
register of the WHO International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/network/primary/en/index.html) or
in ClinicalTrials.gov, which is a data provider to the WHO ICTRP.
The ICMJE endorses these registries because they meet several
criteria. They are accessible to the public at no charge, open to all
prospective registrants, managed by a not-for-proﬁt organization,
have a mechanism to ensure the validity of the registration data,
and are electronically searchable. An acceptable registry must
include the minimum 20-item trial registration dataset (http://
prsinfo.clinicaltrials.gov/trainTrainer/WHO-ICMJE-ClinTrialsgov-
Cross-Ref.pdf or www.who.int/ictrp/network/trds/en/index.html)
at the time of registration and before enrollment of the ﬁrst partic-
ipant. The ICMJE considers inadequate trial registrations missing
any of the 20 data ﬁelds or those that have ﬁelds that contain un-
informative information. Although not a required item, the ICMJE
encourages authors to include a statement that indicates that the
results have not yet been published in a peer-reviewed journal,
and to update the registration with the full journal citation when
the results are published.
The purpose of clinical trial registration is to prevent selective
publication and selective reporting of research outcomes, to pre-
vent unnecessary duplication of research effort, to help patients
and the public knowwhat trials are planned or ongoing into which
they might want to enroll, and to help give ethics review boards
considering approval of new studies a view of similar work and
data relevant to the research they are considering. Retrospective
registration, for example at the time of manuscript submission,
meets none of these purposes. Those purposes apply also to
research with alternative designs, for example observational
studies. For that reason, the ICMJE encourages registration of
research with non-trial designs, but because the exposure or inter-
vention in non-trial research is not dictated by the researchers, the
ICMJE does not require it.
Secondary data analyses of primary (parent) clinical trials
should not be registered as separate clinical trials, but instead
should reference the trial registration number of the primary trial.
The ICMJE encourages posting of clinical trial results in clinical
trial registries but does not require it. The ICMJE will not consider
as prior publication the posting of trial results in any registry that
meets the above criteria if results are limited to a brief (500
word) structured abstract or tables (to include patients enrolled,
key outcomes, and adverse events).
The ICMJE recommends that journals publish the trial registra-
tion number at the end of the abstract. The ICMJE also recommends
that, whenever a registration number is available, authors list this
number the ﬁrst time they use a trial acronym to refer either to
the trial they are reporting or to other trials that they mention in
the manuscript.
Editors may consider whether the circumstances involved in a
failure to appropriately register a clinical trial were likely to have
been intended to or resulted in biased reporting. If an exception
to prospective registration is made, trials must be registered and
the authors should indicate in the publication when registration
was completed and why it was delayed. Editors should publish a
statement indicating why an exceptionwas allowed. The ICMJE em-
phasizes that such exceptions should be rare, and that authors
failing to prospectively register a trial risk its inadmissibility to
our journals.
4. Manuscript preparation and submission
4.1. Preparing a manuscript for submission to a medical journal
4.1.1. General principles
The text of articles reporting original research is usually divided
into Introduction, Methods, Results, and Discussion sections. This
so-called “IMRAD” structure is not an arbitrary publication format
but a reﬂection of the process of scientiﬁc discovery. Articles often
need subheadings within these sections to further organize their
content. Other types of articles, such as meta-analyses, may require
different formats, while case reports, narrative reviews, and edito-
rials may have less structured or unstructured formats.
Electronic formats have created opportunities for adding details
or sections, layering information, cross-linking, or extracting por-
tions of articles in electronic versions. Supplementary electronic-
only material should be submitted and sent for peer review simul-
taneously with the primary manuscript.
4.1.2. Reporting guidelines
Reporting guidelines have been developed for different study
designs; examples include CONSORT (www.consort-statement.
org) for randomized trials, STROBE for observational studies
(http://strobe-statement.org/), PRISMA for systematic reviews and
meta-analyses (http://prisma-statement.org/), and STARD for
studies of diagnostic accuracy (www.stard-statement.org/). Jour-
nals are encouraged to ask authors to follow these guidelines
because they help authors describe the study in enough detail for
it to be evaluated by editors, reviewers, readers, and other re-
searchers evaluating themedical literature. Authors of reviewman-
uscripts are encouraged to describe the methods used for locating,
selecting, extracting, and synthesizing data; this is mandatory for
systematic reviews. Good sources for reporting guidelines are the
EQUATOR Network (www.equator-network.org/home/) and the
NLM's Research Reporting Guidelines and Initiatives (www.nlm.
nih.gov/services/research_report_guide.html).
4.1.3. Manuscript sections
The following are general requirements for reporting within
sections of all study designs and manuscript formats.4.1.3.1. Title page. General information about an article and its au-
thors is presented on a manuscript title page and usually includes
the article title, author information, any disclaimers, sources of sup-
port, word count, and sometimes the number of tables and ﬁgures.
Article title. The title provides a distilled description of the com-
plete article and should include information that, along with the
Abstract, will make electronic retrieval of the article sensitive and
speciﬁc. Reporting guidelines recommend and some journals
require that information about the study design be a part of the title
(particularly important for randomized trials and systematic re-
views and meta-analyses). Some journals require a short title, usu-
ally no more than 40 characters (including letters and spaces) on
the title page or as a separate entry in an electronic submission sys-
tem. Electronic submission systems may restrict the number of
characters in the title.
Author information. Each author's highest academic degrees
should be listed, although some journals do not publish these.
The name of the department(s) and institution(s) or organizations
where the work should be attributed should be speciﬁed. Most
electronic submission systems require that authors provide full
contact information, including land mail and e-mail addresses,
but the title page should list the corresponding authors' telephone
and fax numbers and e-mail address. ICMJE encourages the listingof authors' Open Researcher and Contributor Identiﬁcation
(ORCID).
Disclaimers. An example of a disclaimer is an author's statement
that the views expressed in the submitted article are his or her own
and not an ofﬁcial position of the institution or funder.
Source(s) of support. These include grants, equipment, drugs,
and/or other support that facilitated conduct of the work described
in the article or the writing of the article itself.
Word count. A word count for the paper's text, excluding its ab-
stract, acknowledgments, tables, ﬁgure legends, and references, al-
lows editors and reviewers to assess whether the information
contained in the paper warrants the paper's length, and whether
the submitted manuscript ﬁts within the journal's formats and
word limits. A separate word count for the Abstract is useful for
the same reason.
Number of ﬁgures and tables. Some submission systems require
speciﬁcation of the number of Figures and Tables before uploading
the relevant ﬁles. These numbers allow editorial staff and reviewers
to conﬁrm that all ﬁgures and tables were actually included with
the manuscript and, because Tables and Figures occupy space, to
assess if the information provided by the ﬁgures and tables war-
rants the paper's length and if the manuscript ﬁts within the jour-
nal's space limits.
Conﬂict of Interest declaration. Conﬂict of interest information for
each author needs to be part of themanuscript; each journal should
develop standards with regard to the form the information should
take and where it will be posted. The ICMJE has developed a uni-
form conﬂict of interest disclosure form for use by ICMJE member
journals (www.icmje.org/coi_disclosure.pdf) and the ICMJE encour-
ages other journals to adopt it. Despite availability of the form, ed-
itors may require conﬂict of interest declarations on themanuscript
title page to save the work of collecting forms from each author
prior to making an editorial decision or to save reviewers and
readers the work of reading each author's form.
4.1.3.2. Abstract. Original research, systematic reviews, and meta-
analyses require structured abstracts. The abstract should provide
the context or background for the study and should state the
study's purpose, basic procedures (selection of study participants,
settings, measurements, analytical methods), main ﬁndings (giving
speciﬁc effect sizes and their statistical and clinical signiﬁcance, if
possible), and principal conclusions. It should emphasize new and
important aspects of the study or observations, note important lim-
itations, and not over interpret ﬁndings. Clinical trial abstracts
should include items that the CONSORT group has identiﬁed as
essential (www.consort-statement.org/resources/downloads/
extensions/consort-extension-for-abstracts-2008pdf/). Funding
sources should be listed separately after the Abstract to facilitate
proper display and indexing for search retrieval by MEDLINE.
Because abstracts are the only substantive portion of the article
indexed in many electronic databases, and the only portion many
readers read, authors need to ensure that they accurately reﬂect
the content of the article. Unfortunately, information in abstracts
often differs from that in the text. Authors and editors should
work in the process of revision and review to ensure that informa-
tion is consistent in both places. The format required for structured
abstracts differs from journal to journal, and some journals use
more than one format; authors need to prepare their abstracts in
the format speciﬁed by the journal they have chosen.
The ICMJE recommends that journals publish the clinical trial
registration number at the end of the abstract. The ICMJE also rec-
ommends that, when a registration number is available, authors list
that number the ﬁrst time they use a trial acronym to refer to the
trial they are reporting or to other trials that they mention in the
manuscript. If the data have been deposited in a public repository,
authors should state at the end of the abstract the data set name,
repository name and number.
4.1.3.3. Introduction. Provide a context or background for the study
(that is, the nature of the problem and its signiﬁcance). State the
speciﬁc purpose or research objective of, or hypothesis tested by,
the study or observation. Cite only directly pertinent references,
and do not include data or conclusions from the work being
reported.
4.1.3.4. Methods. The guiding principle of the Methods section
should be clarity about how and why a study was done in a partic-
ular way. The Methods section should aim to be sufﬁciently
detailed such that others with access to the data would be able to
reproduce the results. In general, the section should include only
information that was available at the time the plan or protocol
for the study was being written; all information obtained during
the study belongs in the Results section. If an organization was
paid or otherwise contracted to help conduct the research (exam-
ples include data collection and management), then this should
be detailed in the methods. The Methods section should include a
statement indicating that the research was approved or exempted
from the need for review by the responsible review committee
(institutional or national). If no formal ethics committee is avail-
able, a statement indicating that the research was conducted ac-
cording to the principles of the Declaration of Helsinki should be
included.
4.1.3.4.1. Selection and description of participants
Clearly describe the selection of observational or experimental
participants (healthy individuals or patients, including controls),
including eligibility and exclusion criteria and a description of the
source population. Because the relevance of such variables as age,
sex, or ethnicity is not always known at the time of study design,
researchers should aim for inclusion of representative populations
into all study types and at a minimum provide descriptive data for
these and other relevant demographic variables. If the study was
done involving an exclusive population, for example in only one
sex, authors should justify why, except in obvious cases (e.g., pros-
tate cancer).” Authors should deﬁne how they measured race or
ethnicity and justify their relevance.
4.1.3.4.2. Technical information
Specify the study's main and secondary objectives-usually iden-
tiﬁed as primary and secondary outcomes. Identify methods, equip-
ment (give the manufacturer's name and address in parentheses),
and procedures in sufﬁcient detail to allow others to reproduce
the results. Give references to established methods, including sta-
tistical methods (see below); provide references and brief descrip-
tions for methods that have been published but are not well-
known; describe new or substantially modiﬁed methods, give the
reasons for using them, and evaluate their limitations. Identify pre-
cisely all drugs and chemicals used, including generic name(s),
dose(s), and route(s) of administration. Identify appropriate scien-
tiﬁc names and gene names.
4.1.3.4.3. Statistics
Describe statistical methods with enough detail to enable a
knowledgeable reader with access to the original data to judge its
appropriateness for the study and to verify the reported results.
When possible, quantify ﬁndings and present them with appro-
priate indicators of measurement error or uncertainty (such as con-
ﬁdence intervals). Avoid relying solely on statistical hypothesis
testing, such as p values, which fail to convey important informa-
tion about effect size and precision of estimates. References forthe design of the study and statistical methods should be to stan-
dard works when possible (with pages stated). Deﬁne statistical
terms, abbreviations, and most symbols. Specify the statistical soft-
ware package(s) and versions used. Distinguish prespeciﬁed from
exploratory analyses, including subgroup analyses.
4.1.3.5. Results. Present your results in logical sequence in the text,
tables, and ﬁgures, giving themain ormost important ﬁndings ﬁrst.
Do not repeat all the data in the tables or ﬁgures in the text; empha-
size or summarize only the most important observations. Provide
data on all primary and secondary outcomes identiﬁed in the
Methods Section. Extra or supplementary materials and technical
details can be placed in an appendix where they will be accessible
but will not interrupt the ﬂow of the text, or they can be published
solely in the electronic version of the journal.
Give numeric results not only as derivatives (for example, per-
centages) but also as the absolute numbers fromwhich the deriva-
tives were calculated, and specify the statistical signiﬁcance
attached to them, if any. Restrict tables and ﬁgures to those needed
to explain the argument of the paper and to assess supporting data.
Use graphs as an alternative to tables with many entries; do not
duplicate data in graphs and tables. Avoid nontechnical uses of
technical terms in statistics, such as “random” (which implies a
randomizing device), “normal,” “signiﬁcant,” “correlations,” and
“sample.” Separate reporting of data by demographic variables,
such as age and sex, facilitate pooling of data for subgroups across
studies and should be routine, unless there are compelling reasons
not to stratify reporting, which should be explained.
4.1.3.6. Discussion. It is useful to begin the discussion by brieﬂy
summarizing the main ﬁndings, and explore possible mechanisms
or explanations for these ﬁndings. Emphasize the new and impor-
tant aspects of your study and put your ﬁnings in the context of the
totality of the relevant evidence. State the limitations of your study,
and explore the implications of your ﬁndings for future research
and for clinical practice or policy. Do not repeat in detail data or
other information given in other parts of the manuscript, such as
in the Introduction or the Results section.
Link the conclusions with the goals of the study but avoid un-
qualiﬁed statements and conclusions not adequately supported
by the data. In particular, distinguish between clinical and statisti-
cal signiﬁcance, and avoidmaking statements on economic beneﬁts
and costs unless the manuscript includes the appropriate economic
data and analyses. Avoid claiming priority or alluding to work that
has not been completed. State new hypotheses when warranted,
but label them clearly.
4.1.3.7. References. 4.1.3.7.1. General considerations
Authors should provide direct references to original research
sources whenever possible. References should not be used by au-
thors, editors, or peer reviewers to promote self-interests. Although
references to review articles can be an efﬁcient way to guide
readers to a body of literature, review articles do not always reﬂect
original work accurately. On the other hand, extensive lists of refer-
ences to original work on a topic can use excessive space. Fewer ref-
erences to key original papers often serve as well as more
exhaustive lists, particularly since references can now be added
to the electronic version of published papers, and since electronic
literature searching allows readers to retrieve published literature
efﬁciently.
Do not use conference abstracts as references: they can be cited
in the text, in parentheses, but not as page footnotes. References to
papers accepted but not yet published should be designated as “in
press” or “forthcoming.” Information from manuscripts submitted
but not accepted should be cited in the text as “unpublished obser-
vations” with written permission from the source.
Avoid citing a “personal communication” unless it provides
essential information not available from a public source, in which
case the name of the person and date of communication should
be cited in parentheses in the text. For scientiﬁc articles, obtain
written permission and conﬁrmation of accuracy from the source
of a personal communication.
Some but not all journals check the accuracy of all reference ci-
tations; thus, citation errors sometimes appear in the published
version of articles. To minimize such errors, references should be
veriﬁed using either an electronic bibliographic source, such as
PubMed, or print copies from original sources. Authors are respon-
sible for checking that none of the references cite retracted articles
except in the context of referring to the retraction. For articles pub-
lished in journals indexed in MEDLINE, the ICMJE considers
PubMed the authoritative source for information about retractions.
Authors can identify retracted articles in MEDLINE by searching
PubMed for “Retracted publication [pt]”, where the term “pt” in
square brackets stands for publication type, or by going directly
to the PubMed's list of retracted publications (www.ncbi.nlm.nih.-
gov/pubmed ?termretractedpublication[pt]).
References should be numbered consecutively in the order in
which they are ﬁrst mentioned in the text. Identify references in
text, tables, and legends by Arabic numerals in parentheses.
References cited only in tables or ﬁgure legends should be
numbered in accordance with the sequence established by the ﬁrst
identiﬁcation in the text of the particular table or ﬁgure. The titles
of journals should be abbreviated according to the style used for
MEDLINE (www.ncbi.nlm.nih.gov/nlmcatalog/journals). Journals
vary on whether they ask authors to cite electronic references
within parentheses in the text or in numbered references following
the text. Authors should consult with the journal towhich they plan
to submit their work.
4.1.3.7.2. Style and format
References should follow the standards summarized in the
NLM's International Committee of Medical Journal Editors (ICMJE)
Recommendations for the Conduct, Reporting, Editing and Publica-
tion of Scholarly Work in Medical Journals: Sample References
(www.nlm.nih.gov/bsd/uniform_requirements.html) webpage and
detailed in the NLM's Citing Medicine, 2nd edition (www.ncbi.
nlm.nih.gov/books/NBK7256/). These resources are regularly
updated as new media develop, and currently include guidance
for print documents; unpublished material; audio and visual me-
dia; material on CD-ROM, DVD, or disk; and material on the
Internet.
4.1.3.8. Tables. Tables capture information concisely and display it
efﬁciently; they also provide information at any desired level of
detail and precision. Including data in tables rather than text
frequently makes it possible to reduce the length of the text.
Prepare tables according to the speciﬁc journal's requirements;
to avoid errors it is best if tables can be directly imported into the
journal's publication software. Number tables consecutively in
the order of their ﬁrst citation in the text and supply a title for
each. Titles in tables should be short but self-explanatory, contain-
ing information that allows readers to understand the table's con-
tent without having to go back to the text. Be sure that each table is
cited in the text.
Give each column a short or an abbreviated heading. Authors
should place explanatory matter in footnotes, not in the heading.
Explain all nonstandard abbreviations in footnotes, and use sym-
bols to explain information if needed. Symbols may vary from jour-
nal to journal (alphabet letter or such symbols as *, y, z, x), so checkeach journal's instructions for authors for required practice. Iden-
tify statistical measures of variations, such as standard deviation
and standard error of the mean.
If you use data from another published or unpublished source,
obtain permission and acknowledge that source fully.
Additional tables containing backup data too extensive to pub-
lish in print may be appropriate for publication in the electronic
version of the journal, deposited with an archival service, or
made available to readers directly by the authors. An appropriate
statement should be added to the text to inform readers that this
additional information is available and where it is located. Submit
such tables for consideration with the paper so that they will be
available to the peer reviewers.4.1.3.9. Illustrations (ﬁgures). Digital images of manuscript illustra-
tions should be submitted in a suitable format for print publication.
Most submission systems have detailed instructions on the quality
of images and check them after manuscript upload. For print sub-
missions, ﬁgures should be either professionally drawn and photo-
graphed, or submitted as photographicquality digital prints.
For X-ray ﬁlms, scans, and other diagnostic images, as well as
pictures of pathology specimens or photomicrographs, send high-
resolution photographic image ﬁles. Since blots are used as primary
evidence in many scientiﬁc articles, editors may require deposition
of the original photographs of blots on the journal's website.
Although some journals redraw ﬁgures, many do not. Letters,
numbers, and symbols on ﬁgures should therefore be clear and
consistent throughout, and large enough to remain legible when
the ﬁgure is reduced for publication. Figures should be made as
self-explanatory as possible, since many will be used directly in
slide presentations. Titles and detailed explanations belong in the
legends-not on the illustrations themselves.
Photomicrographs should have internal scale markers. Symbols,
arrows, or letters used in photomicrographs should contrast with
the background. Explain the internal scale and identify the method
of staining in photomicrographs.
Figures should be numbered consecutively according to the or-
der in which they have been cited in the text. If a ﬁgure has been
published previously, acknowledge the original source and submit
written permission from the copyright holder to reproduce it.
Permission is required irrespective of authorship or publisher
except for documents in the public domain.
In the manuscript, legends for illustrations should be on a sepa-
rate page, with Arabic numerals corresponding to the illustrations.
When symbols, arrows, numbers, or letters are used to identify
parts of the illustrations, identify and explain each one clearly in
the legend.4.1.3.10. Units of measurement. Measurements of length, height,
weight, and volume should be reported in metric units (meter, ki-
logram, or liter) or their decimal multiples.
Temperatures should be in degrees Celsius. Blood pressures
should be in millimeters of mercury, unless other units are specif-
ically required by the journal.
Journals vary in the units they use for reporting hematologic,
clinical chemistry, and other measurements. Authors must consult
the Information for Authors of the particular journal and should
report laboratory information in both local and International Sys-
tem of Units (SI).
Editors may request that authors add alternative or non-SI units,
since SI units are not universally used. Drug concentrations may be
reported in either SI or mass units, but the alternative should be
provided in parentheses where appropriate.
4.1.3.11. Abbreviations and symbols. Use only standard abbrevia-
tions; use of nonstandard abbreviations can be confusing to
readers. Avoid abbreviations in the title of the manuscript. The
spelled-out abbreviation followed by the abbreviation in paren-
thesis should be used on ﬁrst mention unless the abbreviation is
a standard unit of measurement.4.2. Sending the manuscript to the journal
Manuscripts should be accompanied by a cover letter or a
completed journal submission form, which should include the
following information:
A full statement to the editor about all submissions and previous
reports that might be regarded as redundant publication of the
same or very similar work. Any such work should be referred to
speciﬁcally and referenced in the new paper. Copies of such mate-
rial should be included with the submitted paper to help the editor
address the situation. See also Section 3.4.2.
A statement of ﬁnancial or other relationships that might lead to
a conﬂict of interest, if that information is not included in the
manuscript itself or in an authors' form. See also Section 2.2.
A statement on authorship. Journals that do not use contribution
declarations for all authors may require that the submission letter
includes a statement that the manuscript has been read and
approved by all the authors, that the requirements for authorship
as stated earlier in this document have been met, and that each
author believes that the manuscript represents honest work if
that information is not provided in another form See also Section
2.1.Contact information for the author responsible for communi-
cating with other authors about revisions and ﬁnal approval of
the proofs, if that information is not included in the manuscript it-
self. The letter or form should inform editors if concerns have been
raised (e.g., via institutional and/or regulatory bodies) regarding
the conduct of the research or if corrective action has been
recommended.
The letter or form should give any additional information that
may be helpful to the editor, such as the type or format of article
in the particular journal that the manuscript represents. If the
manuscript has been submitted previously to another journal, it
is helpful to include the previous editor's and reviewers' comments
with the submitted manuscript, along with the authors' responses
to those comments. Editors encourage authors to submit these pre-
vious communications. Doing so may expedite the review process
and encourages transparency and sharing of expertise.
Many journals provide a presubmission checklist to help the
author ensure that all the components of the submission have
been included. Some journals also require that authors complete
checklists for reports of certain study types (for example, the CON-
SORT checklist for reports of randomized controlled trials). Authors
should look to see if the journal uses such checklists, and send them
with the manuscript if they are requested.
The manuscript must be accompanied by permission to repro-
duce previously published material, use previously published illus-
trations, report information about identiﬁable persons, or to
acknowledge people for their contributions.Available online 9 February 2016
